Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Jul 5;13(1):10927.
doi: 10.1038/s41598-023-37183-0.

Factors associated with carotid intima-media thickness progression in patients with asymptomatic hyperuricemia: insights from the PRIZE study

Yuichi Saito  1 , Atsushi Tanaka  2 , Tomoko Ishizu  3 , Hisako Yoshida  4 , Yoshiaki Kubota  5 , Mamoru Nanasato  6 , Munehide Matsuhisa  7 , Yusuke Ohya  8 , Yoshio Kobayashi  9 , Koichi Node  10 ; PRIZE Study Investigators
Collaborators, Affiliations
Randomized Controlled Trial

Factors associated with carotid intima-media thickness progression in patients with asymptomatic hyperuricemia: insights from the PRIZE study

Yuichi Saito et al. Sci Rep. .

Abstract

Hyperuricemia is reportedly associated with the progression of carotid intima-media thickness (IMT), a surrogate of cardiovascular risks and events. However, factors associated with carotid IMT progression in patients with asymptomatic hyperuricemia are largely unknown. In this post-hoc analysis of the multicenter, randomized PRIZE study, we analyzed data from a total of 326 patients who underwent carotid ultrasonography in a blind manner at baseline and 24 months to evaluate carotid IMT. Mean and maximum IMT at the common carotid artery (CCA) were measured at a central core laboratory. Factors related to the absolute change in mean and maximum IMT from baseline to 24 months were explored. Overall, the adjusted mean [0.0032 (- 0.0214 to 0.0278) mm] and maximum [0.0011 (- 0.0327 to 0.0351) mm] CCA-IMT increased numerically from baseline to 24 months. Multivariable analysis identified higher body mass index, history of atherosclerotic cardiovascular disease (ASCVD), and lower mean CCA-IMT at baseline as significant factors associated with the increase in mean CCA-IMT. In addition, older age and lower mean CCA-IMT at baseline were significant factors for an increased absolute change in the maximum CCA-IMT at 24 months. The present sub-analysis of the PRIZE study showed higher body mass index, history of ASCVD, and older age as significant factors associated with CCA-IMT progression in patients with asymptomatic hyperuricemia. These factors may be considered when identifying the possible risk of atherosclerotic progression in this specific patient population of hyperuricemia.Trial registration: UMIN000012911 and UMIN000041322.

PubMed Disclaimer

Conflict of interest statement

AT received honoraria from Boehringer Ingelheim and research funding from GlaxoSmithKline and Takeda. MM has received honoraria from Sanofi, Takeda Pharmaceutical Company Ltd., Eli Lilly Japan, Mitsubishi Tanabe Pharma Corporation, Astellas Pharma Inc., Novo Nordisk Pharma Ltd., Sumitomo Dainippon Pharmaceutical Company and MSD; research funding from Sysmex Corporation and Nissui; and subsidies or donations from Novartis Pharma, Sanofi, and Novo Nordisk Pharma Ltd. KN has received honoraria from MSD, Astella, AstraZeneca, Novartis Pharma, Ono Pharmaceutical, Daiichi Sankyo, Mitsubishi Tanabe Pharma, Eli Lilly Japan, Boehringer Ingelheim Japan, Takeda Pharmaceutical; Research grant from Asahi Kasei, Astellas, Mitsubishi Tanabe Pharma, Teijin Pharma, Terumo, Boehringer Ingelheim Japan, Eli Lilly and Company, Mochida Pharmaceutical, Fuji Yakuhin; Scholarship from Daiichi Sankyo Healthcare, Teijin Pharma, Medtronic, Bayer Yakuhin. All other authors declare no competing interests.

Figures

Figure 1
Figure 1
Study flow. BMI body mass index, CRP C-reactive protein, eGFR estimated glomerular filtration rate, IMT intima-media thickness.
Figure 2
Figure 2
Relation of age and BMI to change in mean and maximum CCA-IMT. BMI body mass index, CCA common carotid artery, IMT intima-media thickness.
See this image and copyright information in PMC

References

    1. Saito Y, Tanaka A, Node K, Kobayashi Y. Uric acid and cardiovascular disease: A clinical review. J Cardiol. 2021;78(1):51–57. doi: 10.1016/j.jjcc.2020.12.013. - DOI - PubMed
    1. Tavil Y, Kaya MG, Oktar SO, Sen N, Okyay K, Yazici HU, et al. Uric acid level and its association with carotid intima-media thickness in patients with hypertension. Atherosclerosis. 2008;197(1):159–163. doi: 10.1016/j.atherosclerosis.2007.03.008. - DOI - PubMed
    1. Mannarino MR, Pirro M, Gigante B, Savonen K, Kurl S, Giral P, et al. Association between uric acid, carotid intima-media thickness, and cardiovascular events: Prospective results from the IMPROVE study. J. Am. Heart Assoc. 2021;10(11):e020419. doi: 10.1161/JAHA.120.020419. - DOI - PMC - PubMed
    1. Ma M, Wang L, Huang W, Zhong X, Li L, Wang H, et al. Meta-analysis of the correlation between serum uric acid level and carotid intima-media thickness. PLoS ONE. 2021;16(2):e0246416. doi: 10.1371/journal.pone.0246416. - DOI - PMC - PubMed
    1. Willeit P, Tschiderer L, Allara E, Reuber K, Seekircher L, Gao L, et al. Carotid intima-media thickness progression as surrogate marker for cardiovascular risk: Meta-analysis of 119 clinical trials involving 100 667 patients. Circulation. 2020;142(7):621–642. doi: 10.1161/CIRCULATIONAHA.120.046361. - DOI - PMC - PubMed

Publication types

MeSH terms

Associated data